Filmmaker Behind Netflix’s Psychedelics Documentary Is Working on Sequel

September 1, 2021 14:55:07

If you’re interested in psychedelics and have watched the “Adventures in Psychedelics” documentary on Netflix, you may soon be getting a sequel. The documentary’s writer, Donick Cary, recently revealed that a series or film — or both — is on the horizon, hinting at the possibility of a podcast as well.

The “Adventures in Psychedelics” documentary first aired on Netflix in May 2020. However, it took more than a decade to make, with Mike Rosenstein, who was the producer, and Cary interviewing celebrities such as Anthony Bourdain, A$AP Rocky and Carrie Fisher about their experiences with psychedelics.

This documentary, which has stars advising against as well as advocating for psychedelic experiences, is not only entertaining but also enjoyable, with recognizable faces from television and film making it even more relatable. In total, more than 70 interviews were recorded, but fewer than 40 were used. Cary has been in Hollywood for quite a while, having written for “Parks and Recreation,” “New Girl,” “The Late Show with David Letterman” and even “The Simpsons.”

Some of those 70 interviews will be included in the sequel while others will be released as special episodes. The comedic documentary’s sequence release date remains unknown, but Cary did reveal that he would be offering the sequel to Netflix, as the studio had been wonderful to work with. Currently, the documentary has a 72% audience score on Rotten Tomatoes, with an IMDb rating of 6.8/10.

Rosenstein and Cary still retain rights to the title, despite Netflix buying the film, as they see an opportunity to grow a franchise as mainstream interest in psychedelics continues to increase. The two are thinking about establishing a production firm that will focus exclusively on telling psychedelic stories via mixed media productions. Cary notes that, generally, most individuals have revelations to make when it comes to their experiences with psychedelics.

The filmmaker’s documentaries are a good example of a force that’s working to normalize psychedelics. While making the documentary, Cary noticed the huge paradigm shift in how people viewed psychedelics and attributed this change to “How to Change Your Mind” by Michael Pollan. The book documents the history of psychedelic drugs from the ’60s to the recent resurgence in research. It also looks into the therapeutic benefits of psychedelics such as LSD as well as what the substances do to the brain, among many other things. Pollan’s book has helped develop a positive public perception of drugs that were not only illegal but considered dangerous for many decades.

This improved public perception of psychedelics is likely to give any medicinal formulations developed by companies such as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) fertile ground on the market once patients and clinicians learn that approved psychedelic remedies now exist.

NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.